The Evaluation of Survival Rate in Patients with Prostate Cancer by Bayesian Weibull Parametric Accelerated Failure-Time Model.
Bayesian
Kaplan-Meier
Prostate cancer
Survival
Therapy type
Journal
Iranian journal of public health
ISSN: 2251-6093
Titre abrégé: Iran J Public Health
Pays: Iran
ID NLM: 7505531
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
15
04
2021
accepted:
17
06
2021
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
7
2
2023
Statut:
ppublish
Résumé
Prostate cancer is the most prevalent malignancy in men. This study was carried out to determine effective factors on the survival rate of patients diagnosed with prostate cancer in Kerman, Iran. The present study was conducted as a retrospective cohort of 238 patients diagnosed with prostate cancer from 2011 to 2019 in Kerman, Iran. First, the demographic and clinical information of patients were collected. Then, the information on patient survival up to June 2019 was tracked, and their latest statuses of death or survival were recorded. Kaplan-Meier method, log-rank test, and Bayesian Weibull parametric accelerated failure-time model were used for data analysis. Data analysis was carried out by Stata and SAS. The mean age of patients in the diagnosis was 73.28±10.08 year. The patient's 1, 2, 3 and 5-years of overall survival rates were equal to 78.54%, 65.97%, 56.64% and 49.30, respectively. Patients under surgical therapy relatively held longer survival times compared to the rest of the therapies. Patients under chemotherapy had shorter survival times. Age at diagnosis, occupation, chemotherapy, surgery, education, and smoking variables significantly affected patients' survival ( Patients' survival duration increases if the disease is diagnosed at younger ages and its preliminary development stages. Smoking cessation is strongly recommended after diagnosis, as it is associated with a lower survival rate. Patients who underwent radical prostatectomy surgery showed higher survival rates than radiotherapy, hormone ablation, or chemotherapy. Moreover, patients with higher education had more prolonged survival.
Sections du résumé
Background
UNASSIGNED
Prostate cancer is the most prevalent malignancy in men. This study was carried out to determine effective factors on the survival rate of patients diagnosed with prostate cancer in Kerman, Iran.
Methods
UNASSIGNED
The present study was conducted as a retrospective cohort of 238 patients diagnosed with prostate cancer from 2011 to 2019 in Kerman, Iran. First, the demographic and clinical information of patients were collected. Then, the information on patient survival up to June 2019 was tracked, and their latest statuses of death or survival were recorded. Kaplan-Meier method, log-rank test, and Bayesian Weibull parametric accelerated failure-time model were used for data analysis. Data analysis was carried out by Stata and SAS.
Results
UNASSIGNED
The mean age of patients in the diagnosis was 73.28±10.08 year. The patient's 1, 2, 3 and 5-years of overall survival rates were equal to 78.54%, 65.97%, 56.64% and 49.30, respectively. Patients under surgical therapy relatively held longer survival times compared to the rest of the therapies. Patients under chemotherapy had shorter survival times. Age at diagnosis, occupation, chemotherapy, surgery, education, and smoking variables significantly affected patients' survival (
Conclusion
UNASSIGNED
Patients' survival duration increases if the disease is diagnosed at younger ages and its preliminary development stages. Smoking cessation is strongly recommended after diagnosis, as it is associated with a lower survival rate. Patients who underwent radical prostatectomy surgery showed higher survival rates than radiotherapy, hormone ablation, or chemotherapy. Moreover, patients with higher education had more prolonged survival.
Identifiants
pubmed: 36743368
doi: 10.18502/ijph.v51i9.10566
pii: IJPH-51-2108
pmc: PMC9884364
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2108-2116Informations de copyright
Copyright © 2022 Askari Tajabadi et al. Published by Tehran University of Medical Sciences.
Références
Urology. 2003 Dec;62(6):1035-9
pubmed: 14665350
Clin Med Insights Oncol. 2016 Mar 23;10(Suppl 1):11-9
pubmed: 27042152
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2011 Jan 10;29(2):235-41
pubmed: 21135285
Ann Oncol. 2009 Mar;20(3):556-63
pubmed: 19073863
Eur J Cancer. 2020 May;130:204-210
pubmed: 32229417
Br J Cancer. 2008 Dec 2;99(11):1786-93
pubmed: 18985045
Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):665-672
pubmed: 29700008
JAMA. 2011 Jun 22;305(24):2548-55
pubmed: 21693743
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Asian Pac J Cancer Prev. 2018 Jun 25;19(6):1533-1541
pubmed: 29936728
Cancer. 2009 Jul 1;115(13):2863-71
pubmed: 19466697
Urology. 2004 Mar;63(3):518-22
pubmed: 15028449
Prostate Int. 2018 Mar;6(1):31-35
pubmed: 29556487
J Appl Stat. 2011 Mar;38(2):591-603
pubmed: 21475617
Stat Methods Med Res. 2016 Apr;25(2):793-806
pubmed: 23117407
Urol Oncol. 2018 Nov;36(11):475-487
pubmed: 30309766
Minerva Urol Nefrol. 2019 Oct;71(5):508-515
pubmed: 30957475
Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1261-6
pubmed: 10889379
World J Surg Oncol. 2020 Feb 24;18(1):42
pubmed: 32093688
In Vivo. 1994 May-Jun;8(3):439-43
pubmed: 7803731
Asian Pac J Cancer Prev. 2014;15(2):883-6
pubmed: 24568512
Am J Mens Health. 2008 Jun;2(2):165-71
pubmed: 19477780
Med J Islam Repub Iran. 2021 Feb 02;35:16
pubmed: 33996667
Scand J Work Environ Health. 1992 Aug;18(4):209-15
pubmed: 1411362
J Endourol. 2008 Jan;22(1):97-104
pubmed: 18326071